Search

Displaying results 2731 - 2740 of 8974 in total
  1. Drug

    Hydroxyzine

    go.drugbank.com/drugs/DB00557
    ApprovedInvestigational

    [A189753] Hydroxyzine is also used for generalized anxiety disorder, tension caused by psychoneurosis, and other conditions with manifestations of anxiety.[L9677] … [L9677] The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect.

  2. Drug

    Tetrachlorodecaoxide

    go.drugbank.com/drugs/DB05389
    Approved

    The trial is being conducted in Germany at the University of Heidelberg and the National Centre for Tumor Diseases. … The Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Nebivolol

    go.drugbank.com/drugs/DB04861
    ApprovedInvestigational

    [A182579] Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol].

    Categories: Antihypertensive Agents Indicated for Hypertension
  4. Drug

    Hydroxyamphetamine

    go.drugbank.com/drugs/DB09352
    Approved

    Among the minor side effects from its use are: change in color vision, difficulty seeing at night, dry mouth, headache, increased sensitivity of eyes to sunlight, muscle stiffness or tightness and temporary … Hydroxyamphetamine is intended mainly as local eye drops for diagnostic purposes. It is indirect sympathomimetic agent which cause dilation of the eye pupil before diagnostic test.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Agomelatine

    go.drugbank.com/drugs/DB06594
    ApprovedInvestigational

    In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011. … Agomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005.

  6. Drug

    Brexucabtagene autoleucel

    go.drugbank.com/drugs/DB15699
    ApprovedInvestigational

    [L15148] Brexucabtagene autoleucel was granted full approval by the FDA on July 24, 2020 for the treatment of MCL and acute lymphoblastic leukemia (ALL), and is currently available through Kite Pharma … [A216153, A216158] More recently, chimeric antigen receptor (CAR) T cell therapies have been developed that modify a patient's own T cells using viral transduction to bind to and destroy cancerous cells

    Categories: Receptors, Antigen, T-Cell, CD19-Directed Genetically Modified Autologous T-cell Immunotherapies
  7. Drug

    Ibutilide

    go.drugbank.com/drugs/DB00308
    Approved

    It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR).

  8. Drug

    Fluvastatin

    go.drugbank.com/drugs/DB01095
    ApprovedInvestigational

    Fluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. … HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis.

    Categories: Hypolipidemic Agents Indicated for Hyperlipidemia
  9. Drug

    Sipavibart

    go.drugbank.com/drugs/DB21908
    ApprovedInvestigational

    [A274098] It works by binding to the SARS-CoV-2 spike protein receptor binding domain (RBD), neutralize the virus and preventing its entry into the host cell. … [A274088] Sipavibart is approved for the pre-exposure prophylaxis treatment of COVID-19 in immunocompromised patients.[L53418]

    Categories: Antiinfectives for Systemic UseSynonyms: Gamma1 heavy chain Homo sapiens (1-455) [VH (Homo sapiens IGHV3-9*01 (94.9%) -(IGHD) -IGHJ1*01 (90.9%) L123>T (120), CDR-IMGT [8.8.18] (26-33.51-58.97-114)) (1-125) -Homo sapiens IGHG1*03, G1m3, nG1m1
  10. Drug

    Suzetrigine

    go.drugbank.com/drugs/DB18927
    ApprovedInvestigational

    signal transmission, making it a desirable therapeutic target for treatment of pain. … Suzetrigine is a Na<sub>V</sub>1.8 voltage-gated sodium channel blocker with analgesic properties[A264948] Na<sub>V</sub>1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain